Antibody-based therapeutic interventions: possible strategy to counter chikungunya viral infection

[1]  M. Diamond,et al.  Dermal and muscle fibroblasts and skeletal myofibers survive chikungunya virus infection and harbor persistent RNA , 2019, PLoS pathogens.

[2]  L. Castellano,et al.  Immunoglobulin Therapy in a Patient With Severe Chikungunya Fever and Vesiculobullous Lesions , 2019, Front. Immunol..

[3]  H. Lee,et al.  Development of a Specific CHIKV-E2 Monoclonal Antibody for Chikungunya Diagnosis , 2019, Virologica Sinica.

[4]  James E. Crowe,et al.  A lipid-encapsulated mRNA encoding a potently neutralizing human monoclonal antibody protects against chikungunya infection , 2019, Science Immunology.

[5]  M. Koopmans,et al.  The possible role of cross-reactive dengue virus antibodies in Zika virus pathogenesis , 2019, PLoS pathogens.

[6]  T. Ross,et al.  Vaccination with a chikungunya virus-like particle vaccine exacerbates disease in aged mice , 2019, PLoS neglected tropical diseases.

[7]  G. Simmons,et al.  Antiviral Functions of Monoclonal Antibodies against Chikungunya Virus , 2019, Viruses.

[8]  Vedana Vaidhyanathan,et al.  Chikungunya in Infants and Children: Is Pathogenesis Increasing? , 2019, Viruses.

[9]  D. Fremont,et al.  Optimal therapeutic activity of monoclonal antibodies against chikungunya virus requires Fc-FcγR interaction on monocytes , 2019, Science Immunology.

[10]  G. Ippolito,et al.  Tropism of the Chikungunya Virus , 2019, Viruses.

[11]  S. Weaver,et al.  Chikungunya as a paradigm for emerging viral diseases: Evaluating disease impact and hurdles to vaccine development , 2019, PLoS neglected tropical diseases.

[12]  E. Goldman,et al.  Selection and characterization of protective anti‐chikungunya virus single domain antibodies , 2019, Molecular immunology.

[13]  M. R. Donalísio,et al.  Excess Mortality and Causes Associated with Chikungunya, Puerto Rico, 2014–2015 , 2018, Emerging infectious diseases.

[14]  U. Markert,et al.  Zika virus infection in human placental tissue explants is enhanced in the presence of dengue virus antibodies in-vitro , 2018, Emerging Microbes & Infections.

[15]  N. Câmara,et al.  Cellular and Molecular Immune Response to Chikungunya Virus Infection , 2018, Front. Cell. Infect. Microbiol..

[16]  D. Weiner,et al.  Synthetic DNA-Encoded Monoclonal Antibody Delivery of Anti-CTLA-4 Antibodies Induces Tumor Shrinkage In Vivo. , 2018, Cancer research.

[17]  F. Rosso,et al.  Chikungunya in solid organ transplant recipients, a case series and literature review , 2018, Transplant infectious disease : an official journal of the Transplantation Society.

[18]  J. Bhattacharya,et al.  Broadly neutralizing antibodies in HIV-1 treatment and prevention , 2018, Therapeutic advances in vaccines and immunotherapy.

[19]  Andrew M Wollacott,et al.  Extending human IgG half-life using structure-guided design , 2018, mAbs.

[20]  H. Rothan,et al.  Current concerns and perspectives on Zika virus co-infection with arboviruses and HIV. , 2018, Journal of autoimmunity.

[21]  M. Cavaleri,et al.  Monoclonal antibodies as anti-infective products: a promising future? , 2018, Clinical Microbiology and Infection.

[22]  Catharine I Paules,et al.  Monoclonal Antibodies for Emerging Infectious Diseases - Borrowing from History. , 2018, The New England journal of medicine.

[23]  M. Puszczewicz,et al.  Chikungunya virus: a rheumatologist's perspective. , 2018, Clinical and experimental rheumatology.

[24]  L. Rénia,et al.  Antibody-mediated enhancement aggravates chikungunya virus infection and disease severity , 2018, Scientific Reports.

[25]  M. P. Griffin,et al.  Safety, Tolerability and Pharmacokinetics of MEDI8897, an Extended Half-life Single-dose Respiratory Syncytial Virus Prefusion F-targeting Monoclonal Antibody Administered as a Single Dose to Healthy Preterm Infants , 2018, The Pediatric infectious disease journal.

[26]  Qiang Chen,et al.  Development of Antibody Therapeutics against Flaviviruses , 2017, International journal of molecular sciences.

[27]  A. Powers.  Vaccine and Therapeutic Options To Control Chikungunya Virus , 2017, Clinical Microbiology Reviews.

[28]  Ali Zaid,et al.  Chikungunya: vaccines and therapeutics , 2017, F1000Research.

[29]  Arghya Das,et al.  Hidden burden of chikungunya in North India; A prospective study in a tertiary care centre. , 2017, Journal of infection and public health.

[30]  S. Sardi,et al.  First Detection of Chikungunya Virus in Breast Milk. , 2017, The Pediatric infectious disease journal.

[31]  L. Castano-Jaramillo,et al.  [Vertical transmission of chikungunya virus infection. Case Report]. , 2017, Revista chilena de pediatria.

[32]  P. Braga-Neto,et al.  Immunoglobulin-responsive chikungunya encephalitis: two case reports , 2017, Journal of NeuroVirology.

[33]  M. Diamond,et al.  Therapeutic administration of a recombinant human monoclonal antibody reduces the severity of chikungunya virus disease in rhesus macaques , 2017, PLoS neglected tropical diseases.

[34]  Penny A. Rudd,et al.  Chikungunya virus: an update on the biology and pathogenesis of this emerging pathogen. , 2017, The Lancet. Infectious diseases.

[35]  D. Weissman,et al.  Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge , 2017, Nature Communications.

[36]  L. Castellano,et al.  Chikungunya virus infection with severe neurologic manifestations: report of four fatal cases. , 2017, Revista da Sociedade Brasileira de Medicina Tropical.

[37]  I. Sam,et al.  The neutralizing role of IgM during early Chikungunya virus infection , 2017, PloS one.

[38]  M. Sheikh,et al.  Therapeutic antibodies for infectious diseases , 2017, Bulletin of the World Health Organization.

[39]  Justin M. Richner,et al.  Therapy with CTLA4-Ig and an antiviral monoclonal antibody controls chikungunya virus arthritis , 2017, Science Translational Medicine.

[40]  S. Krishna,et al.  Molecular Mimicry between Chikungunya Virus and Host Components: A Possible Mechanism for the Arthritic Manifestations , 2017, PLoS neglected tropical diseases.

[41]  E. Hildt,et al.  Identification of Functional Determinants in the Chikungunya Virus E2 Protein , 2017, PLoS neglected tropical diseases.

[42]  M. Heise,et al.  Animal Models of Chikungunya Virus Infection and Disease. , 2016, The Journal of infectious diseases.

[43]  A. Clayton.  Monoclonal Antibodies as Prophylactic and Therapeutic Agents Against Chikungunya Virus. , 2016, The Journal of infectious diseases.

[44]  S. Weaver,et al.  Development of Vaccines for Chikungunya Fever. , 2016, The Journal of infectious diseases.

[45]  M. Landry.  Immunoglobulin M for Acute Infection: True or False? , 2016, Clinical and Vaccine Immunology.

[46]  N. Sardesai,et al.  Rapid and Long-Term Immunity Elicited by DNA-Encoded Antibody Prophylaxis and DNA Vaccination Against Chikungunya Virus , 2016, The Journal of infectious diseases.

[47]  W. Koff,et al.  Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop , 2016, Journal of Virology.

[48]  Sunit Maity,et al.  Broadly neutralizing antibodies for therapy of viral infections , 2016 .

[49]  I. Sam,et al.  Detection of Persistent Chikungunya Virus RNA but not Infectious Virus in Experimental Vertical Transmission in Aedes aegypti from Malaysia. , 2016, The American journal of tropical medicine and hygiene.

[50]  M. Diamond,et al.  Neutralizing Monoclonal Antibodies Block Chikungunya Virus Entry and Release by Targeting an Epitope Critical to Viral Pathogenesis. , 2015, Cell reports.

[51]  D. Fremont,et al.  Broadly Neutralizing Alphavirus Antibodies Bind an Epitope on E2 and Inhibit Entry and Egress , 2015, Cell.

[52]  E. Saphire,et al.  Potent Antibody Protection against an Emerging Alphavirus Threat , 2015, Cell.

[53]  J. Porta,et al.  Cryo-EM structures elucidate neutralizing mechanisms of anti-chikungunya human monoclonal antibodies with therapeutic activity , 2015, Proceedings of the National Academy of Sciences.

[54]  Marc Lecuit,et al.  Chikungunya virus pathogenesis: From bedside to bench. , 2015, Antiviral research.

[55]  J. Chu,et al.  A potent neutralizing IgM mAb targeting the N218 epitope on E2 protein protects against Chikungunya virus pathogenesis , 2015, mAbs.

[56]  M. Diamond,et al.  Isolation and Characterization of Broad and Ultrapotent Human Monoclonal Antibodies with Therapeutic Activity against Chikungunya Virus. , 2015, Cell host & microbe.

[57]  B. Hoen,et al.  French guidelines for the management of chikungunya (acute and persistent presentations). November 2014. , 2015, Medecine et maladies infectieuses.

[58]  G. Rezza.  Do we need a vaccine against chikungunya? , 2015, Pathogens and global health.

[59]  V. Sambri,et al.  Persistence of anti–chikungunya virus–specific antibodies in a cohort of patients followed from the acute phase of infection after the 2007 outbreak in Italy , 2015, New microbes and new infections.

[60]  N. Wauquier,et al.  Control of immunopathology during chikungunya virus infection. , 2015, The Journal of allergy and clinical immunology.

[61]  A. Hey.  History and Practice: Antibodies in Infectious Diseases , 2015, Microbiology spectrum.

[62]  L. Ng,et al.  Sero-Prevalence and Cross-Reactivity of Chikungunya Virus Specific Anti-E2EP3 Antibodies in Arbovirus-Infected Patients , 2015, PLoS neglected tropical diseases.

[63]  S. Halstead.  Dengue Antibody-Dependent Enhancement: Knowns and Unknowns , 2014, Microbiology spectrum.

[64]  B. Haynes,et al.  Polyreactivity and Autoreactivity among HIV-1 Antibodies , 2014, Journal of Virology.

[65]  N. Wauquier,et al.  Long-term persistence of Chikungunya virus neutralizing antibodies in human populations of North Eastern Thailand , 2014, Virology Journal.

[66]  David F. Tucker,et al.  Exposure of Epitope Residues on the Outer Face of the Chikungunya Virus Envelope Trimer Determines Antibody Neutralizing Efficacy , 2014, Journal of Virology.

[67]  Y. Choong,et al.  Principles and application of antibody libraries for infectious diseases , 2014, Biotechnology Letters.

[68]  K. Ikuta,et al.  Monoclonal antibody targeting chikungunya virus envelope 1 protein inhibits virus release. , 2014, Virology.

[69]  J. Schiller,et al.  Why HIV Virions Have Low Numbers of Envelope Spikes: Implications for Vaccine Development , 2014, PLoS pathogens.

[70]  S. Cherian,et al.  Antiviral Perspectives for Chikungunya Virus , 2014, BioMed research international.

[71]  M. Diamond,et al.  Chikungunya Viruses That Escape Monoclonal Antibody Therapy Are Clinically Attenuated, Stable, and Not Purified in Mosquitoes , 2014, Journal of Virology.

[72]  B. Yan,et al.  First Experimental In Vivo Model of Enhanced Dengue Disease Severity through Maternally Acquired Heterotypic Dengue Antibodies , 2014, PLoS pathogens.

[73]  P. Roques,et al.  Novel Attenuated Chikungunya Vaccine Candidates Elicit Protective Immunity in C57BL/6 mice , 2013, Journal of Virology.

[74]  O. Nicholson,et al.  Immunogenicity and safety of a tetravalent measles-mumps-rubella-varicella vaccine: an open-labeled, randomized trial in healthy Korean children , 2013, Clinical and experimental vaccine research.

[75]  A. Pyke,et al.  Neutralizing monoclonal antibodies to the E2 protein of chikungunya virus protects against disease in a mouse model. , 2013, Clinical immunology.

[76]  D. Lowy,et al.  Durable Antibody Responses Following One Dose of the Bivalent Human Papillomavirus L1 Virus-Like Particle Vaccine in the Costa Rica Vaccine Trial , 2013, Cancer Prevention Research.

[77]  M. Diamond,et al.  Chronic Joint Disease Caused by Persistent Chikungunya Virus Infection Is Controlled by the Adaptive Immune Response , 2013, Journal of Virology.

[78]  A. Suhrbier,et al.  A Neutralizing Monoclonal Antibody Targeting the Acid-Sensitive Region in Chikungunya Virus E2 Protects from Disease , 2013, PLoS neglected tropical diseases.

[79]  S. Blutt,et al.  The Gastrointestinal Frontier: IgA and Viruses , 2013, Front. Immunol..

[80]  J. Cullen,et al.  Chikungunya Virus Host Range E2 Transmembrane Deletion Mutants Induce Protective Immunity against Challenge in C57BL/6J Mice , 2013, Journal of Virology.

[81]  M. Diamond,et al.  Structural analyses at pseudo atomic resolution of Chikungunya virus and antibodies show mechanisms of neutralization , 2013, eLife.

[82]  Antonio Lanzavecchia,et al.  Broadly neutralizing antiviral antibodies. , 2013, Annual review of immunology.

[83]  Cheng‐I Wang,et al.  Use of human monoclonal antibodies to treat Chikungunya virus infection. , 2013, The Journal of infectious diseases.

[84]  Angela Chow,et al.  Longitudinal Analysis of the Human Antibody Response to Chikungunya Virus Infection: Implications for Serodiagnosis and Vaccine Development , 2012, Journal of Virology.

[85]  Nicolas Gangneux,et al.  Chikungunya virus infection of corneal grafts. , 2012, The Journal of infectious diseases.

[86]  D. Baltimore,et al.  Vectored immunoprophylaxis protects humanized mice from mucosal HIV transmission , 2012, Retrovirology.

[87]  D. Baltimore,et al.  Vectored ImmunoProphylaxis Protects Humanized Mice from Mucosal HIV Transmission , 2012, Nature Medicine.

[88]  Scott C Weaver,et al.  Chikungunya virus and prospects for a vaccine , 2012, Expert review of vaccines.

[89]  B. Tang.  The cell biology of Chikungunya virus infection , 2012, Cellular microbiology.

[90]  P. Gasque,et al.  Arthritogenic alphaviruses—an overview , 2012, Nature Reviews Rheumatology.

[91]  O. Faye,et al.  Landscape Ecology of Sylvatic Chikungunya Virus and Mosquito Vectors in Southeastern Senegal , 2012, PLoS neglected tropical diseases.

[92]  C. Midgley,et al.  Structural Analysis of a Dengue Cross-Reactive Antibody Complexed with Envelope Domain III Reveals the Molecular Basis of Cross-Reactivity , 2012, The Journal of Immunology.

[93]  L. Rénia,et al.  Early Appearance of Neutralizing Immunoglobulin G3 Antibodies Is Associated With Chikungunya Virus Clearance and Long-term Clinical Protection , 2012, The Journal of infectious diseases.

[94]  J. Tong,et al.  Early neutralizing IgG response to Chikungunya virus in infected patients targets a dominant linear epitope on the E2 glycoprotein , 2012, EMBO molecular medicine.

[95]  Esther G. L. Koh,et al.  Chikungunya Virus Neutralization Antigens and Direct Cell-to-Cell Transmission Are Revealed by Human Antibody-Escape Mutants , 2011, PLoS pathogens.

[96]  A. Takada,et al.  Antibody-dependent enhancement of Marburg virus infection. , 2011, The Journal of infectious diseases.

[97]  M. Carneiro-Sampaio,et al.  IgG Placental Transfer in Healthy and Pathological Pregnancies , 2011, Clinical & developmental immunology.

[98]  E. Wang,et al.  Novel Chikungunya Vaccine Candidate with an IRES-Based Attenuation and Host Range Alteration Mechanism , 2011, PLoS pathogens.

[99]  K. Vijayakumar,et al.  Clinical Profile of Chikungunya Patients during the Epidemic of 2007 in Kerala, India , 2011, Journal of global infectious diseases.

[100]  Yee‐Shin Lin,et al.  Molecular mimicry between virus and host and its implications for dengue disease pathogenesis , 2011, Experimental biology and medicine.

[101]  L. Ng,et al.  Entomological investigation and control of a chikungunya cluster in Singapore. , 2011, Vector borne and zoonotic diseases.

[102]  P. Desprès,et al.  Chikungunya Virus Envelope-Specific Human Monoclonal Antibodies with Broad Neutralization Potency , 2011, The Journal of Immunology.

[103]  L. Rénia,et al.  Persistent Arthralgia Induced by Chikungunya Virus Infection is Associated with Interleukin-6 and Granulocyte Macrophage Colony-Stimulating Factor , 2011, The Journal of infectious diseases.

[104]  R. Kashyap,et al.  Detection of viral antigen, IgM and IgG antibodies in cerebrospinal fluid of Chikungunya patients with neurological complications , 2010, Cerebrospinal Fluid Research.

[105]  Y. Leo,et al.  Evaluation of Chikungunya Diagnostic Assays: Differences in Sensitivity of Serology Assays in Two Independent Outbreaks , 2010, PLoS neglected tropical diseases.

[106]  Thibaut Larcher,et al.  Chikungunya Virus Arthritis in Adult Wild-Type Mice , 2010, Journal of Virology.

[107]  B. Autran,et al.  Persistent Chronic Inflammation and Infection by Chikungunya Arthritogenic Alphavirus in Spite of a Robust Host Immune Response , 2010, The Journal of Immunology.

[108]  A. P. Adams,et al.  Genome-Scale Phylogenetic Analyses of Chikungunya Virus Reveal Independent Emergences of Recent Epidemics and Various Evolutionary Rates , 2010, Journal of Virology.

[109]  Nathan M. Sherer,et al.  Virus Cell-to-Cell Transmission , 2010, Journal of Virology.

[110]  Karine Labadie,et al.  Chikungunya disease in nonhuman primates involves long-term viral persistence in macrophages. , 2010, The Journal of clinical investigation.

[111]  S. Higgs,et al.  A VLP vaccine for epidemic Chikungunya virus protects non-human primates against infection , 2010, Nature Medicine.

[112]  B. Autran,et al.  Destructive arthritis in a patient with chikungunya virus infection with persistent specific IgM antibodies , 2009, BMC infectious diseases.

[113]  Thomas Müller,et al.  Development of a Mouse Monoclonal Antibody Cocktail for Post-exposure Rabies Prophylaxis in Humans , 2009, PLoS neglected tropical diseases.

[114]  Nicolas Gangneux,et al.  Prophylaxis and Therapy for Chikungunya Virus Infection , 2009, The Journal of infectious diseases.

[115]  S. M. N. Arosha Senanayake,et al.  Vertical transmission in chikungunya infection. , 2009, The Ceylon medical journal.

[116]  Philip R. Johnson,et al.  Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys , 2009, Nature Medicine.

[117]  K. Krishnamoorthy,et al.  Burden of chikungunya in India: estimates of disability adjusted life years (DALY) lost in 2006 epidemic. , 2009, Journal of vector borne diseases.

[118]  Hemant J Purohit,et al.  Neurological complications of Chikungunya virus infection. , 2009, Neurology India.

[119]  S. Lemon,et al.  In vitro selection of a neutralization-resistant hepatitis C virus escape mutant , 2008, Proceedings of the National Academy of Sciences.

[120]  P. Quénel,et al.  Atypical Chikungunya virus infections: clinical manifestations, mortality and risk factors for severe disease during the 2005–2006 outbreak on Réunion , 2008, Epidemiology and Infection.

[121]  Paola Sapienza,et al.  Long Term Persistence , 2008 .

[122]  R. Tesh,et al.  An animal model for studying the pathogenesis of chikungunya virus infection. , 2008, The American journal of tropical medicine and hygiene.

[123]  A. Brault,et al.  Arbovirus evolution in vivo is constrained by host alternation , 2008, Proceedings of the National Academy of Sciences.

[124]  F. Arenzana‐Seisdedos,et al.  Multidisciplinary Prospective Study of Mother-to-Child Chikungunya Virus Infections on the Island of La Réunion , 2008, PLoS medicine.

[125]  D. Mavalankar,et al.  Increased Mortality Rate Associated with Chikungunya Epidemic, Ahmedabad, India , 2008, Emerging infectious diseases.

[126]  P. Puthavathana,et al.  Role of Dendritic Cells in Antibody-Dependent Enhancement of Dengue Virus Infection , 2008, Journal of Virology.

[127]  Fabrice Chrétien,et al.  A Mouse Model for Chikungunya: Young Age and Inefficient Type-I Interferon Signaling Are Risk Factors for Severe Disease , 2008, PLoS pathogens.

[128]  S. Higgs,et al.  A Single Mutation in Chikungunya Virus Affects Vector Specificity and Epidemic Potential , 2007, PLoS pathogens.

[129]  A. Powers,et al.  Changing patterns of chikungunya virus: re-emergence of a zoonotic arbovirus. , 2007, The Journal of general virology.

[130]  M. Diamond,et al.  CD40-CD40 Ligand Interactions Promote Trafficking of CD8+ T Cells into the Brain and Protection against West Nile Virus Encephalitis , 2007, Journal of Virology.

[131]  J. Englund.  The influence of maternal immunization on infant immune responses. , 2007, Journal of comparative pathology.

[132]  Didier Raoult,et al.  Chikungunya outbreaks--the globalization of vectorborne diseases. , 2007, The New England journal of medicine.

[133]  A. Le Tertre,et al.  Chikungunya Disease Outbreak, Reunion Island , 2006, Emerging infectious diseases.

[134]  V. Vaillant,et al.  Novel Chikungunya Virus Variant in Travelers Returning from Indian Ocean Islands , 2006, Emerging infectious diseases.

[135]  D. Knowles,et al.  Human immunodeficiency virus 1 Nef suppresses CD40-dependent immunoglobulin class switching in bystander B cells , 2006, Nature Immunology.

[136]  H. Vollmers,et al.  The "early birds": natural IgM antibodies and immune surveillance. , 2005, Histology and histopathology.

[137]  Wen-I Lee,et al.  Hyper-IgM1 syndrome with interstitial pneumonia and diarrhea caused by coxsackievirus B4 in a 3-month-old infant. , 2005, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[138]  Y. Kawaoka,et al.  Antibody‐dependent enhancement of viral infection: molecular mechanisms and in vivo implications , 2003, Reviews in medical virology.

[139]  P. Dunman,et al.  Passive immunization as prophylaxis: when and where will this work? , 2003, Current opinion in pharmacology.

[140]  S. Pitlik,et al.  Possible benefit of intravenous immunoglobulin therapy in a lung transplant recipient with West Nile virus encephalitis , 2002, Transplant infectious disease : an official journal of the Transplantation Society.

[141]  B. Lidbury,et al.  Specific Ablation of Antiviral Gene Expression in Macrophages by Antibody-Dependent Enhancement of Ross River Virus Infection , 2000, Journal of Virology.

[142]  J. Drake,et al.  Mutation rates among RNA viruses. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[143]  J. Yata,et al.  Regulation of human IgG subclass production by cytokines. IFN-gamma and IL-6 act antagonistically in the induction of human IgG1 but additively in the induction of IgG2. , 1994, Journal of immunology.

[144]  J M Hughes,et al.  Infectious disease surveillance: a crumbling foundation. , 1994, Science.

[145]  H. Ochiai,et al.  Infection enhancement of influenza A NWS virus in primary murine macrophages by anti‐hemagglutinin monoclonal antibody , 1992, Journal of medical virology.

[146]  S. Halstead,et al.  Measurement of antibody-dependent infection enhancement of four dengue virus serotypes by monoclonal and polyclonal antibodies. , 1990, The Journal of general virology.

[147]  J. R. Brubaker,et al.  Variants of Venezuelan equine encephalitis virus that resist neutralization define a domain of the E2 glycoprotein. , 1990, Virology.

[148]  D. Montefiori,et al.  ANTIBODY-DEPENDENT ENHANCEMENT OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTION , 1988, The Lancet.

[149]  L. Dalgarno,et al.  Location of a major antigenic site involved in Ross River virus neutralization. , 1988, Virology.

[150]  C. Schmaljohn,et al.  Antibody-selected variation and reversion in Sindbis virus neutralization epitopes , 1986, Journal of virology.

[151]  T. Hirano,et al.  Purification to homogeneity and characterization of human B-cell differentiation factor (BCDF or BSFp-2). , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[152]  J. S. Porterfield,et al.  Antibody-mediated enhancement of rabies virus infection in a mouse macrophage cell line (P388D1). , 1984, The Journal of general virology.

[153]  R. Tesh,et al.  Transovarial transmission of dengue viruses by mosquitoes: Aedes albopictus and Aedes aegypti. , 1983, The American journal of tropical medicine and hygiene.

[154]  Katherine Spindler,et al.  Rapid evolution of RNA genomes. , 1982, Science.

[155]  J. S. Porterfield.  Antibody-mediated enhancement of rabies virus , 1981, Nature.

[156]  R. Ross.  The Newala epidemic: III. The virus: isolation, pathogenic properties and relationship to the epidemic , 1956, Journal of Hygiene.

[157]  G. Rezza.  Chikungunya is back in Italy: 2007-2017. , 2018, Journal of travel medicine.

[158]  Penny A. Rudd,et al.  Mouse Models of Chikungunya Virus. , 2016, Methods in molecular biology.

[159]  S. Maity,et al.  Broadly neutralizing antibodies for therapy of viral infections , 2016 .

[160]  J. Vlak,et al.  Neglected Tropical Diseases : Effective Chikungunya Virus-like Particle Vaccin . , 2013 .

[161]  D. Fremont,et al.  University of Groningen Development of a Highly Protective Combination Monoclonal Antibody Therapy against Chikungunya Virus Pal, , 2013 .

[162]  T. Hohdatsu,et al.  The role of IgG subclass of mouse monoclonal antibodies in antibody-dependent enhancement of feline infectious peritonitis virus infection of feline macrophages , 2005, Archives of Virology.

[163]  H. Rousseau,et al.  [Percutaneous peripheral atherectomy with the Simpson catheter. Long term results]. , 1991, Journal des maladies vasculaires.

[164]  L. Kramer,et al.  Intrinsic factors affecting vector competence of mosquitoes for arboviruses. , 1983, Annual review of entomology.

[165]  M C ROBINSON,et al.  An epidemic of virus disease in Southern Province, Tanganyika Territory, in 1952-53. I. Clinical features. , 1955, Transactions of the Royal Society of Tropical Medicine and Hygiene.